Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB036C combinations in advanced lung cancer
NCT07229599Phase 2Recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- May 2025
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MHB036C in non-small cell lung cancer (NSCLC), sponsored by Minghui Pharmaceutical, Inc.. Started May 2025; status: recruiting.
02
Drugs
MHB036C
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07229599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229599.